Market Overview:
The global varicella-zoster virus (VZV) treatment market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of herpes zoster, rising awareness about VZV infections and their treatments, and the launch of new products. Based on type, the global VZV treatment market is segmented into acyclovir, valacyclovir, famciclovir, and others. Acyclovir is currently the most commonly used drug for treating VZV infections and is expected to maintain its dominance during the forecast period. However, valacyclovir is expected to grow at a higher CAGR due to its better absorption properties as compared with acyclovir. Based on application, the global VZV treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies,.
 Treatment Industry Outlook.svg)
Product Definition:
Varicella-Zoster Virus (VZV) is a virus that causes two diseases: chickenpox and shingles. Chickenpox is a highly contagious disease that affects mostly children. It causes an itchy rash, blisters, and fever. Shingles is caused by the reactivation of the VZV virus years after you have had chickenpox. It can cause pain, burning, or tingling sensations in the skin where it appears; these symptoms may persist for months or even years.
Acyclovir:
Acyclovir is a medication used to treat the chickenpox and shingles. It's active ingredient, called acyclic nucleoside analog, is approved by the Food and Drug Administration (FDA) for treatment of varicella-zoster virus (VZV), which causes chickenpox and shingles. According to CDC estimates, about one out of three people in the U.
Valacyclovir:
Valacyclovir is an antiviral drug used for the treatment of viral infections including shingles, herpes simplex virus (HSV), varicella-zoster virus (VZV), and cytomegalovirus. It works by blocking the action of a enzyme called polymerase which is required for viral replication.
Application Insights:
The other application segment includes individuals who have been exposed to the chickenpox virus but have no symptoms. These individuals are referred to as susceptible hosts and include immunocompromised patients, household contacts of infected individuals, and healthcare workers. The susceptible host segment held the largest share in 2017 owing to high prevalence of VZV infections among these populations.
Individuals affected with varicella infection often suffer from bacterial superinfection during primary healing process at the site of injury due largely on inadequate drainage caused by secondary skin infection with microorganisms including Staphylococcus aureus, Escherichia coli, Bacteroides fragilis among others which may result in further complications if not treated timely with antibiotics. This factor is anticipated to drive demand for antiviral drugs such as acyclovir or valacyclovir over the forecast period thereby contributing towards market growth across all applications globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers, high awareness levels coupled with the availability of effective treatment methods are some factors attributing to its largest share. Moreover, increasing government initiatives for raising awareness about varicella zoster virus infection and supporting treatment options are expected to fuel its growth over the forecast period.
Asia Pacific is estimated to be fastest growing region during the forecast period owing to rising disposable income leading to an increase in demand for healthcare products & services resulting in increased adoption of VZV treatments such as acyclovir, valacyclovir, famciclovir etc., especially online pharmacies that cater specifically towards Asian countries such as India and China have witnessed significant growth over past few years which is further anticipated boost regional market growth during future years due to rise in purchasing power along with growing target population base.
Growth Factors:
- Increasing incidence of varicella-zoster virus (VZV) infections across the globe.
- Growing demand for better and more effective VZV treatments.
- Rising number of research and development activities for novel VZV therapies.
- increasing awareness about the benefits of early diagnosis and treatment of VZV infections among patients, caregivers, and healthcare professionals worldwide . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Varicella-Zoster Virus (VZV) Treatment Market Research Report
By Type
Acyclovir, Valacyclovir, Famciclovir, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Roche, Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Varicella-Zoster Virus (VZV) Treatment Market Report Segments:
The global Varicella-Zoster Virus (VZV) Treatment market is segmented on the basis of:
Types
Acyclovir, Valacyclovir, Famciclovir, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Merck
- Pfizer
- Novartis
- Abbott
- GlaxoSmithKline
- Sanofi
- Eli Lilly
- Astrazeneca
- Johnson & Johnson
 Treatment Market Overview.svg)
Highlights of The Varicella-Zoster Virus (VZV) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Varicella-Zoster Virus (VZV) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Varicella-Zoster Virus (VZV) treatment is a combination of antiviral medications that help to prevent the virus from replicating and causing symptoms. Treatment may include acyclovir, famciclovir, or valacyclovir.
Some of the key players operating in the varicella-zoster virus (vzv) treatment market are Roche, Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson.
The varicella-zoster virus (vzv) treatment market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Varicella-Zoster Virus (VZV) Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Varicella-Zoster Virus (VZV) Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Varicella-Zoster Virus (VZV) Treatment Market - Supply Chain
4.5. Global Varicella-Zoster Virus (VZV) Treatment Market Forecast
4.5.1. Varicella-Zoster Virus (VZV) Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Varicella-Zoster Virus (VZV) Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Varicella-Zoster Virus (VZV) Treatment Market Absolute $ Opportunity
5. Global Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
5.3.1. Acyclovir
5.3.2. Valacyclovir
5.3.3. Famciclovir
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Varicella-Zoster Virus (VZV) Treatment Demand Share Forecast, 2019-2026
9. North America Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
9.7.1. Acyclovir
9.7.2. Valacyclovir
9.7.3. Famciclovir
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Varicella-Zoster Virus (VZV) Treatment Demand Share Forecast, 2019-2026
10. Latin America Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
10.7.1. Acyclovir
10.7.2. Valacyclovir
10.7.3. Famciclovir
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Varicella-Zoster Virus (VZV) Treatment Demand Share Forecast, 2019-2026
11. Europe Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
11.7.1. Acyclovir
11.7.2. Valacyclovir
11.7.3. Famciclovir
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Varicella-Zoster Virus (VZV) Treatment Demand Share, 2019-2026
12. Asia Pacific Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
12.7.1. Acyclovir
12.7.2. Valacyclovir
12.7.3. Famciclovir
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Varicella-Zoster Virus (VZV) Treatment Demand Share, 2019-2026
13. Middle East & Africa Varicella-Zoster Virus (VZV) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Varicella-Zoster Virus (VZV) Treatment Market Size and Volume Forecast by Type
13.7.1. Acyclovir
13.7.2. Valacyclovir
13.7.3. Famciclovir
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Varicella-Zoster Virus (VZV) Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Varicella-Zoster Virus (VZV) Treatment Market: Market Share Analysis
14.2. Varicella-Zoster Virus (VZV) Treatment Distributors and Customers
14.3. Varicella-Zoster Virus (VZV) Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astrazeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Johnson & Johnson
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
